Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa

References

• Aita JF. 1982. Why patients with Parkinson’s disease fall. J Am Med Assoc 247:515–516.
   Web of Science ®Google Scholar
• Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. 2003. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in United States. Ann Intern Med 138:891–897.
   PubMed Web of Science ®Google Scholar
• Beulens JW, Sierkasma A, Schoafsma G, Kok FJ, Struys EA,Jakobs C, Hendriks HF. 2005. Kinetics ofHcy metabolism after moderate alcohol consumption. Alcohol Clin Exp Res 29:739–745.
   PubMed Web of Science ®Google Scholar
• Blasco C, Caballeria J, Deulofen R, Lligona A, Pares A, Lluis JM, Gual A, Rodes J. 2005. Prevalence and mechanisms of hyperhomocysteinemia in chronic alcoholics. Alcohol Clin Exp Res 29:1044–1048.
   PubMed Web of Science ®Google Scholar
• Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D’Agostino RB, Wilson PW, Wolf PA. 1999. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham study. Ann Int Med 131:352–355.
   PubMed Web of Science ®Google Scholar
• Bottiglieri T. 1996. Folate, vitamin B12 and neuropsychiatric disorders. Nutr Rev 54:382–390.
   PubMed Web of Science ®Google Scholar
• Brouwer IA, van Dusseldorp M, Thomas CMG, Duran M, Hautvast JGAJ, Eskes TKAB, Steegers-Theunissen RP. 1999. Low-dose folic acid supplementation decrease plasma homocysteine concentrations: A randomized trial. Am J Clin Nutr 69:99–104.
   PubMed Web of Science ®Google Scholar
• Cappuccio FP, Bell R, Perry IJ, Gilg J, Ueland PM, Refsum H, Sagnella GA, Jeffery S, Cook DG. 2002. Homocysteine levels in men and woman of different ethnic and cultural background living in England. Atherosclerosis 164:95–102.
   PubMed Web of Science ®Google Scholar
• Clarke R, Frost C, Leroy V, Collins R. 1998. For homocysteine lowering trialists collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. Br Med J 316:894–898.
   PubMedGoogle Scholar
• D’Angelo A, Selhub J. 1997. Homocysteine and thrombotic disease. Blood 90:1–11.
   PubMed Web of Science ®Google Scholar
• Daly D, Miller JW, Nadeau MR, Selhub J. 1997. The effect of L- dopa administration and folate deficiency on plasma homocysteine concentrations in rats. J Nutr Biochem 8:634–640.
   Web of Science ®Google Scholar
• Dankner R, Chetrit A, Lubin F, Sela BA. 2004. Life-style habits and homocysteine levels in an elderly population. Aging Clin Exp Res 16:437–442.
   PubMed Web of Science ®Google Scholar
• de Bree A, Verschuren WM, Kromhout D, Kluijtmans LA, Blom HJ. 2002. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 54:599–618.
   PubMed Web of Science ®Google Scholar
• de Lau LML, Koudstaal PJ, van Meurs JBJ, Uitterlinden AG, Hofman A, Breteler MMB. 2005. Methylenetetrahydrofolate reductase C677T genotype and PD. Ann Neurol 57:927–930.
   PubMed Web of Science ®Google Scholar
• Dedoussis GV, Panagiotakos DB, Chrysohoou C, Pitsavon C, Zampelas A, Choumerianou D, Stefanadis C. 2004. Effect of interaction between adherence to a Mediterranean diet and the methylenetetrahydrofolate reductase 677C T mutation on homocysteine concentrations in healthy adults: The ATTICA study. Am J Clin Nutr 80:849–854.
   PubMed Web of Science ®Google Scholar
• Diaz-Arrastia R. 2000. Homocysteine and neurological disease. Arch Neurol 57:1422–1428.
   PubMedGoogle Scholar
• Dierkes J, Westphal S. 2005. Effect of drugs on homocysteine concentrations. Semin Vasc Med 5:124–139.
   PubMedGoogle Scholar
• Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattoson MP. 2002. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem 80:101–110.
   PubMed Web of Science ®Google Scholar
• Fassbender K, Mielke O, Bertsch T, Nafe B, Froschen S, Hennerici M. 1999. Homocysteine in cerebral microangiography and microangiopathy. Lancet 353:1586–1587.
   PubMed Web of Science ®Google Scholar
• Fuller RW, Perry KW, Hemrick-Luecke SK. 1984. Tropolone antagonism of the L-dopa-induced elevation of S-adenosyl- homocysteine: S-adenosilmethionine ratio but not depletion of adrenaline in rathypothalamus. J Pharm Pharmacol 36:419–420. Gillet MJ, Burnett JR. 2005. Alcohol-associated severe hyper- homocysteinemia. Ann Clin Biochem 42:304–307.
   PubMedGoogle Scholar
• Husemoen LL, Thomsen TF, Fenger M, Jorgensen T. 2004. Effect of lifestyle factors on plasma total homocysteine concentrations in relation to MTHFR (C677T) genotype Inter99(7). EurJ Clin Nutr 58:1142–1150.
   PubMed Web of Science ®Google Scholar
• Kruger WD, Evans AA, Wang L. 2000. Polymorphisms in the CBS gene associated with decreased risk of coronary artery disease and increased responsiveness to total homocysteine lowering by folic acid. Mol Genet Metab 70:53–60.
   PubMed Web of Science ®Google Scholar
• Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, Buttner T, Woitalla D, Muller T. 1998. Elevated plasma levels of homocysteine in Parkinson’s disease. Eur Neurol 40:225–227.
   PubMed Web of Science ®Google Scholar
• Lamberti P, Zoccolella S, Armenise E, Lamberti SV, Fraddosio A, de Mari M, Iliceto G, Livrea P. 2005. Hyperhomocysteinemia in L-dopa treated Parkinson’s disease patients: Effect of cobalamin and folate administration. Eur J Neurol 12:365–368.
   PubMed Web of Science ®Google Scholar
• Le Witt PA, Nyholm D. 2004. New developments in levodopa therapy. Neurology 62:S9 –S16.
   Web of Science ®Google Scholar
• McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, Hannan MT, Cupples LA, Kiel DP. 2004. Homocysteine as a predictive factor for hip fracture in older persons. New Engl J Med 350:2042–2049.
   PubMed Web of Science ®Google Scholar
• Melamed E, Offen D, Shirvan A, Ziv I. 2000. Levodopa an exotoxin or a therapeutic drug? J Neurol 247:II135 -II139.
   PubMed Web of Science ®Google Scholar
• Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. 2003. Effect of L-dopa on plasma homocysteine in PD patients. Relationship to B-vitamin status. Neurology 60:1125–1129.
   PubMed Web of Science ®Google Scholar
• Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. 1997. Effect of L-dopa and the catechol-O- methyltransferase inhibitor Ro 41–0960 on sulphur amino acid metabolites in rats. Clin Neuropharmacol 20:55–66.
   PubMed Web of Science ®Google Scholar
• Muller T. 2002. Dopaminergic substation in Parkinson’s disease. Expert Opin Pharmacother 3:1393–1403.
   PubMedGoogle Scholar
• Muller T, Woitalla D, Kuhn W. 2003. Benefit of folic acid supplementation in Parkinsonian patients treated with levodopa. J Neurol Neurosurg Psychiatry 74:549.
   PubMed Web of Science ®Google Scholar
• Nakaso K, Yasui K, Kowa H, Kusumi M, Ueda K, Yoshimoto Y, Takeshima T, Sesaki K, Nakushima K. 2003. Hypertrophy ofIMC of carotid artery in Parkinson’s disease is associated with L-dopa, homocysteine and MTHFR genotype. J Neurol Sci207:19–23.
   PubMed Web of Science ®Google Scholar
• National Research Council. 1998. Dietary reference intakes for thiamine, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantotheic acid, biotin and choline. Washington, DC: National Academy Press.
   Google Scholar
• Nurk E, Tell GS, Vollset SE, Nygard O, Refsum H, Nilsen RM, Ueland PM. 2004. Changes in lifestyle and plasma total homocysteine: The Hordaland homocysteine studt. Am J Clin Nutr 79:812–819.
   PubMed Web of Science ®Google Scholar
• Nygard O, Volsen SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvale G. 1995. Total plasma homocysteine and cardiovascular risk profile. The Hordaland homocysteine study. J Am Med Assoc 274:1526–1533.
   PubMed Web of Science ®Google Scholar
• Ordez LA, Wurtman RJ. 1974. Folic acid deficiency and methyl group metabolism in rat brain: Effects of L-dopa. Arch Biochem Biophys 160:372–376.
   PubMed Web of Science ®Google Scholar
• O’Suilleabhain PE, Bottiglieri T, Dewey RB, Jr, Sharma S, Diaz-Arrastia R. 2004a. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson’s disease. Mov Disord 19:1403–1408.
   PubMed Web of Science ®Google Scholar
• O’Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB, Jr, Bottiglieri T, Diaz-Arrastia R. 2004b. Elevated plasma homocysteine level in patients with Parkinson disease: Motor, affective and cognitive associations. Arch Neurol 61:865–868.
   PubMed Web of Science ®Google Scholar
• Petra V, Martijn BK. 2004. A healthy lifestyle lowers homocysteine, but should we care? Am J Clin Nutr 79:713–714.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Lang AE. 2004. Homocysteine levodopa. Should Parkinson’s disease patients receive preventive therapy? Neurology 63:886–891.
   PubMed Web of Science ®Google Scholar
• Riggs KM, Spiro A, Tucker KL, Rush D. 1996. Relations ofvitamin B6, folate, and homocysteine to cognitive performance in the normative aging study. Am J Clin Nutr 63:306–314.
   PubMed Web of Science ®Google Scholar
• Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. 2003. Elevated plasma homocysteine levels in patients treated with L-dopa. Arch Neurol 60:59–64.
   PubMed Web of Science ®Google Scholar
• Sato Y, Iwamoto J, Kanoko T, Satoh K. 2005. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson’s disease. Am J Med 118:1250–1255.
   PubMed Web of Science ®Google Scholar
• Sato Y, Kaji M, Tsuru T, Oizumi K. 2001. Risk factors for hip fracture among elderly patients with Parkinson’s disease. J Neurol Sci 82:89–93.
   Google Scholar
• Saw SM, Yuan JM, Ong CN, Arakawa K, Lee HP, Coetzee GA, Yu MC. 2001. Genetic, dietary and other lifestyle determinants of plasma homocysteine concentrations in middle-aged and older Chinese men and woman in Singapore. Am J Clin Nutr 73:232–239.
   PubMed Web of Science ®Google Scholar
• Shelhub J, Miller JW. 1992. The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethio- nine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 55:131–138.
   PubMed Web of Science ®Google Scholar
• Siniscalchi A. 2004. Hyperhomocysteinemia in neurologic diseases. Recenti Prog Med 95:371–375.
   PubMedGoogle Scholar
• Siniscalchi A, Mancuso F, Gallelli L, Ferreri Ibbadu G, Mercuri NB, De Sarro G. 2005. Increase in plasma homocysteine levels induced by drug treatments in neurological patients. Pharmacol Res 52:367–375.
   PubMed Web of Science ®Google Scholar
• Strandhagen E, Zetterberg M, Aires N, Palmer M, Rymo L, Blennow K, Landaas S, Thelle DS. 2004. The methylenetetradydrofolate reductaseC677Tpolymorphismisamajordeterminantofcoffee- induced increase ofplasma homocysteine: A randomized placebo controlled study. Int J Mol Med 23:811–815.
   Google Scholar
• Taufek HR, Bone AH. 1980. Influence of exogenous L-3,4-di- hydrohyphenylalanine (L-dopa) on the methionine and S-ade- nosylmethionine concentrations in the brain and other tissues. Biochem Soc Trans 8:62–63.
   PubMedGoogle Scholar
• Urgert R, van Vliet T, Zock PL, Katan MB. 2000. Heavy coffee consumption and plasma homocysteine: A randomized controlled trial in healthy volunteers. Am J Clin Nutr 72:1107–1110.
   PubMed Web of Science ®Google Scholar
• van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, de Groot LC, Hofman A, Witteman JC, van Leeuwen JP, Breteler MM, Lips P, Pols HA, Uitterlinden AG. 2004. Homocysteine levels and the risk of osteoporotic fracture. New Engl J Med 350:2033–2041.
   PubMed Web of Science ®Google Scholar
• Wald DS, Bishop L, Wald NJ, Law M, Hennessy E, Weir D, McPartlin J, Scott J. 2001. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med 161:695–700.
   PubMedGoogle Scholar
• Woitalla D, Kuhn W, Muller T. 2004. MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson’s disease. J Neural Transm Suppl 68:15–20.
   PubMedGoogle Scholar
• Yasui K, Nakaso K, Kowa K, Takeshima T, Nakashima K. 2003. Levodopa-induced hyperhomocysteinemia in Parkinson’s disease. Acta Neurol Scand 108:66–67.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Lamberti P, Armenise E, de Mari M, Lamberti SV, Mastronardi R, Fraddosio A, Iliceto G, Livrea P. 2005. Plasma homocysteine levels in Parkinson’s disease: Role of antiParkinsonian medications. Parkinsonism Relat Disord 11: 131–133.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Lamberti P, Iliceto G, Diroma C, Armenise E, Defazio G, Lamberti SV, Fraddosio A, de Mari M, Livrea P. 2005. Plasma homocysteine levels in L-dopa-treated Parkinson’s disease patients with cognitive dysfunctions. Clin Chem Lab Med 43:1107–1110.
   PubMed Web of Science ®Google Scholar